Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug941 | Clofazimine Wiki | 0.71 |
| drug2906 | Physiotherapy - Manual Therapy Wiki | 0.71 |
| drug4740 | some risk factors that might be correlated with TMD Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013705 | Temporomandibular Joint Disorders NIH | 1.00 |
| D002012 | Bruxism NIH | 0.71 |
| D007592 | Joint Diseases NIH | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0003763 | Bruxism HPO | 0.71 |
| HP:0001367 | Abnormal joint morphology HPO | 0.50 |
Navigate: Correlations HPO
There are 2 clinical trials
RATIONALE OF THE OBSERVATION STUDY: This study aims to observe which patients with temporomandibular disorder improve more following a physiotherapy program of four sessions. Knowing the characteristics of patients who have the most significant improvements could help clinician advise or advise against physiotherapy for the treatment of temporomandibular disorders. STUDY PROCEDURES The study will be conducted at the Istituto Stomatologico Italiano. Patients diagnosed with Temporomandibular Disorder will be recruited in the gnathological and neuromuscular gnathological departments. The physiotherapists of the Craniomandibular Physiotherapy Service will perform physiotherapy therapy, which consists of four physiotherapy sessions [lasting 30 minutes, about once a week] over a month. Before starting the treatment, participants will be asked to answer some questions and questionnaires concerning their state of health (e.g. quality of sleep) with particular reference to Temporomandibular Disorder (e.g. location and duration of pain). The intensity of pain at the beginning of the study and the end of the observed therapy (one month) will then be monitored. EXPECTED BENEFITS FROM THE STUDY AND EXPECTED BENEFITS FOR THE PATIENT The benefits are the discovery of new knowledge in the field of therapeutic choice for patients with temporomandibular disorder.
Description: Pain intensity will be calculated by averaging the ratings of current pain, average pain in the past week, and worst pain in the past week using the Visual Analogue Scale (VAS), consisting of a horizontal line measuring 10 cm (without marks), with "no pain" written at the left extremity, and "worst pain imaginable" at the right extremity. Patients will be educated to trace a perpendicular line on the horizontal line to intend the pain intensity. The distance from the 0 points will be after measured in millimetres. The VAS is a reliable and valid scale to assess pain intensity as an outcome measure in intervention studies. Based on the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) recommendations about TMD , a reduction of at least 30% of the VAS score for pain intensity is considered clinically significant. Consequently, a reduction in the total VAS score [≥ 30%] will be defined as a good outcome
Measure: Pain Intensity: Visual Analogue Scale [VAS] Time: one month, three monthsDescription: COVID Stress Scales (CSS): The CSS are a 36-items scales composed of five domains: danger and contamination fears, fears about economic consequences, xenophobia, compulsive checking and reassurance-seeking, and traumatic stress symptoms about COVID-19. All items are scored on a 5-point scale ranging from 0 to 4, with elevated values indicating high COVID-related impact. Current evidence revealed that CSS worked with acceptable values of reliability and validity.
Measure: COVID-19 Related Distress Time: three monthsDescription: Health-related quality of life was evaluated through a visual analogue scale (range 0-100) representing 'worst' to 'best' possible health.
Measure: General health variables Time: three monthsDescription: An 11-point Numerical Rating Scale [NRS] was adopted to estimate sleep quality, where 0 is 'best possible sleep' and 10 is 'worst possible sleep'. This scale was used to assess the average sleep quality related to the preceding 6-months at baseline and related to the preceding 3-months at the follow-up.
Measure: Sleep Quality Time: three monthsDescription: The Hospital Anxiety and Depression Scales (HADS): Depression and anxiety were measured with the Italian version of the HADS at baseline and at the follow-up assessment. HADS is made up of two 7 items subscales [anxiety: HADS-A; depression: HADS-D]. The score ranges from 0 to 21 with higher values indicating greater levels of anxiety and depression. HADS has excellent concurrent validity in comparison to other depression/anxiety scales, and adequate to excellent internal consistency (HADS-A [0.68-0.93]; HADS-D [0.67-0.90]).
Measure: Depression and anxiety Time: three monthsDescription: Coping Strategies Questionnaire 27 (CSQ-27): The Italian version of the CSQ-27 was applied to assess strategies for coping with pain at baseline and at the follow-up. 40 This questionnaire includes six domains: Distraction, Catastrophizing, Ignoring pain sensations, Distancing from pain, Coping self-statements, and Praying. Participants were asked to score the specific strategies utilising a seven-point Likert scale for each domain. Possible scores range from 0 "never do that" to 6 "aways do that".
Measure: Coping Strategies Time: three monthsDescription: Central Sensitization Inventory (CSI): Participants completed the part A of the Italian version of the CSI at baseline and follow-up. This questionnaire is composed of 25 items with five possible answers ranging from 'never' (0) to 'always' (4) concerning current health symptoms. Significant test-retest reliability and internal consistency were found for CSI in people with and without pain.
Measure: Central Sensitization Time: three monthsDescription: The Italian version of the Research Diagnostic Criteria for TMD (RDC/TMD) questionnaire Axis II Graded Chronic Pain Scale (GCPS) version -2.0 [www.rdc-tmdinternational.org] was administered by following the DC/TMD protocol recommendations. In this study, the GCPS was used to appraise facial pain severity related to the preceding 6-months at baseline and related to the last 3 months at follow-up. This scale unifies pain intensity and pain-related disability into one of the five ordinal categories of chronic facial pain severity. 67 Pain intensity is measured through the characteristic pain intensity (CPI) score (range: 0-100). A disability score (range: 0-6) is obtained from a combination of the number of disability days and the disability level.
Measure: Characteristic pain intensity and disability Time: three monthsDescription: The Italian version of the RDC/TMD questionnaire Axis II Oral Behaviours Checklist (OBC) [www.rdc-tmdinternational.org] was administered at baseline and at the follow-up by following the DC/TMD protocol recommendations. The OBC is a 21 item questionnaire with five possible answers ranging from 'none of the time' (0) to 'all of the time' (4), referring to activities related to the preceding month involving the jaw such as clenching or grinding the teeth.
Measure: Oral Behaviour Time: three monthsThis study will take place in Egypt. Undergraduate students from different faculties of the Egyptian Universities will participate. The study will begin in December 2020.
Description: Fonseca Questionnaire
Measure: prevalence of TMDs in Egyptian university students Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports